Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
Tóm tắt
Từ khóa
Tài liệu tham khảo
1994
2000
Castelli, 1984, Epidemiology of coronary heart disease: The Framingham Study, Am J Med, 76, 4, 10.1016/0002-9343(84)90952-5
Kannel, 1971, Serum cholesterol, lipoproteins, and the risk of coronary heart disease, Ann Intern Med, 74, 1, 10.7326/0003-4819-74-1-1
Verschuren, 1995, Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the Seven Countries Study, JAMA, 274, 131, 10.1001/jama.274.2.131
Stamler, 1986, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.256.20.2823
Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001
Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615
1995, Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S), Lancet, 345, 1274, 10.1016/S0140-6736(95)90926-5
Sacks, 1998, Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial, Circulation, 97, 1446, 10.1161/01.CIR.97.15.1446
1998, Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902
Beisiegel, 1998, Lipoprotein metabolism, Eur Heart J, 19, A20
Russell, 1992, Cholesterol biosynthesis and metabolism, Cardiovasc Drugs Ther, 6, 103, 10.1007/BF00054556
Illingworth, 2000, Management of hypercholesterolemia, Med Clin North Am, 84, 23, 10.1016/S0025-7125(05)70205-4
Moghadasian, 1999, Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, Life Sci, 65, 1329, 10.1016/S0024-3205(99)00199-X
Witztum, 1996, Drugs used in the treatment of hyperdyslipidemias, 875
Bays, 1999, Lipid-altering drugs in development, Drugs R D, 1, 463, 10.2165/00126839-199901060-00010
Davidson, 1999, Colesevelam hydrochloride (Cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects, Arch Intern Med, 159, 1893, 10.1001/archinte.159.16.1893
Hallikainen, 2000, Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner, J Nutr, 130, 767, 10.1093/jn/130.4.767
Miettinen, 1999, Regulation of cholesterol metabolism by dietary plant sterols, Curr Opin Lipidology, 10, 9, 10.1097/00041433-199902000-00003
van Heek, 1997, In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461, J Pharmacol Exp Ther, 283, 157
van Heek, 2000, Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663, Br J Pharmacol, 129, 1748, 10.1038/sj.bjp.0703235
van Heek M, Farley C, Compton D, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. In press.
van Heek, 2000, The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically, Atherosclerosis, 151, 155, 10.1016/S0021-9150(00)80703-0
Zhu, 1999, The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor, AAPS Pharm Sci, 1, S24
Davis, 2000, Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption, Eur Heart J, 21, 636
Davis, 1995, The hypocholesterolemic activity of the potent cholesterol absorption inhibitor SCH58235 alone and in combination with HMG CoA reductase inhibitors, Program and abstracts of Drugs Affecting Lipid Metabolism
Davis, 2000, The cholesterol inhibitor ezetimibe inhibits the development of atherosclerosis in apo E knockout (-/-) mice fed low fat and Western diets, Atherosclerosis, 151, 133, 10.1016/S0021-9150(00)80601-2
van Heek, 2001, Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese, hyperinsulinemic hamsters, Diabetes, 50, 1330, 10.2337/diabetes.50.6.1330
van Heek, 2001, The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys, Eur J Pharmacol, 415, 79, 10.1016/S0014-2999(01)00825-1
Davis HR Jr, Pula KK, Alton KB, et al. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor ezetimibe in combination with HMG-CoA reductase inhibitors in dogs. Metab Clin Exp. In press.
Knopp, 2001, Effect of ezetimibe on serum concentrations of lipid-soluble vitamins, Atherosclerosis, 2, 90, 10.1016/S1567-5688(01)80226-9
Zhu, 2000, Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo, Clin Pharmacol Ther, 67, 152
Bauer, 2001, Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin, Clin Pharmacol Ther, 69, P5
Keung, 2001, Ezetimibe does not affect the pharmacokinetics of oral contraceptives, Clin Pharmacol Ther, 69, P55
Statkevich, 2001, Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide, Clin Pharmacol Ther, 69, P67
Kosoglou, 2001, Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe, Atherosclerosis, 2, 38, 10.1016/S1567-5688(01)80026-X
Kosoglou, 2001, Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications, Atherosclerosis, 2, 89, 10.1016/S1567-5688(01)80222-1
1964, 114
1993, Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), JAMA, 269, 3015, 10.1001/jama.269.23.3015
Friedewald, 1972, Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499
Harris, 1995, Comparison of two scoring systems used to monitor diets in outpatient clinical trials, J Cardiovasc Risk, 2, 359, 10.1097/00043798-199508000-00012
Saltzman, 1985, Adverse reaction terminology standardization: A report of Schering-Plough's use of the WHO dictionary and the formation of the WHO Adverse Reaction Terminology Users Group (WUG) Consortium, Drug Inf J, 10, 35, 10.1177/009286158501900106
Cilla, 1996, Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening, J Clin Pharmacol, 36, 604, 10.1002/j.1552-4604.1996.tb04224.x
Saito, 1991, Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study, Arterioscler Thromb, 11, 816, 10.1161/01.ATV.11.4.816
Stamler, 2000, Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity, JAMA, 284, 311, 10.1001/jama.284.3.311
Kosoglou, 2000, Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin, Atherosclerosis, 151, 135, 10.1016/S0021-9150(00)80612-7
Kosoglou, 2000, Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol, Program and abstracts of the Third International Congress on Coronary Artery Disease—from Prevention to Intervention
Kosoglou, 2000, Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin, Program and abstracts of the Third International Congress on Coronary Artery Disease—from Prevention to Intervention
Kosoglou, 2001, Pharmacodynamic interactions between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin, J Am Coll Cardiol, 37, 229A